Figure 5. Ruxolitinib suppresses the mRNA expression of inflammatory cytokines in EBV-infected T- or NK-cells.

(A and B) EBV-infected T- or NK-cell lines were treated with ruxolitinib, as indicated, for 24 h. The RNA was extracted and subjected to quantitative PCR assays. (A) IFN-γ; (B) TNF-ɑ; (C and D), the PBMCs from patients with CAEBV were treated with ruxolitinib, as indicated, for 24 h. The RNA was extracted and used for quantitative PCR assays. (C) IFN-γ; (D) TNF-ɑ.